Originally published at sbhager.com Sandy Brian Hager Reading in the latest FT Weekend about NovoNordisk’s recent moves to corner the market for weight loss drugs, I was reminded of an eye-opening article from Rana Foroohar late last year. In that piece, the always-sharp Foroohar discusses the emergence of new blockbuster drugs known as semaglutides. These […]
Continue Reading